Retraction: Icariin ameliorates palmitate-induced insulin resistance through reducing thioredoxin-interacting protein (TXNIP) and suppressing ER stress in C2C12 myotubes

, Frontiers Editorial Office

doi:10.3389/fphar.2023.1299165

RETRACTION article

Front. Pharmacol. , 06 October 2023

Sec. Ethnopharmacology

Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1299165

Retraction: Icariin ameliorates palmitate-induced insulin resistance through reducing thioredoxin-interacting protein (TXNIP) and suppressing ER stress in C2C12 myotubes

This article is a retraction of:

RETRACTED: Icariin Ameliorates Palmitate-Induced Insulin Resistance Through Reducing Thioredoxin-Interacting Protein (TXNIP) and Suppressing ER Stress in C2C12 Myotubes
1. Read original article

Frontiers Editorial Office*

A Retraction of the Original Research Article
Icariin ameliorates palmitate-induced insulin resistance through reducing thioredoxin-interacting protein (TXNIP) and suppressing ER stress in C2C12 myotubes

by Li M, Zhang Y, Cao Y, Zhang D, Liu L, Guo Y and Wang C (2018). Front. Pharmacol. 9:1180. doi: 10.3389/fphar.2018.01180

The journal retracts the 2018 article cited above.

Following publication, concerns were raised regarding the integrity of the images in the published figures. Image duplication concerns were identified in Figures 1C, 2B, 6C, E, and 7E. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies. As a result, the data and conclusions of the article have been deemed unreliable and the article has been retracted.

This retraction was approved by the Chief Editors of Frontiers in Pharmacology and the Chief Executive Editor of Frontiers. The authors have not responded to correspondence regarding this retraction.

Citation: Frontiers Editorial Office (2023) Retraction: Icariin ameliorates palmitate-induced insulin resistance through reducing thioredoxin-interacting protein (TXNIP) and suppressing ER stress in C2C12 myotubes. Front. Pharmacol. 14:1299165. doi: 10.3389/fphar.2023.1299165

Received: 22 September 2023; Accepted: 22 September 2023;
Published: 06 October 2023.

Approved by:

Michael Heinrich, University College London, United Kingdom

Copyright © 2023 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, cmVzZWFyY2guaW50ZWdyaXR5QGZyb250aWVyc2luLm9yZw==

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Retraction: Icariin ameliorates palmitate-induced insulin resistance through reducing thioredoxin-interacting protein (TXNIP) and suppressing ER stress in C2C12 myotubes

94% of researchers rate our articles as excellent or good

94% of researchers rate our articles as excellent or good